Latest
finance.yahoo.com Market update
EMV Capital: ProAxsis eyes COPD market breakthrough with Imperial College London study
EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev and ProAxsis managing director Dr Louise Ryan Murphy joined Proactive's Stephen Gunnion to discuss the company's commercial transformation and the opportunity emerging from its Imperial College London COPD study. Iliev said EMV Capital has supported ProAxsis since its Queen's University Belfast spin-out, highlighting progress towards operational breakeven and a recent …
Main company
🇬🇧 United Kingdom
Read at finance.yahoo.com